BioSpace News Archive

Amneal Pharmaceuticals, Inc. announced its results for the fourth quarter and full year ended December 31, 2020.

- Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021- - Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis - - Announced Main Analysis of Phase 2 CALVID-1 Trial of IMU-838 Showing Evidence of Clinical Activity in Patients with Moderate COVID-19 -

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo ® (nivolumab) in Combination with Cabometyx ® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab)

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will present at the Jefferies Plasma Summit on Thursday, March 11, 2021 , at 10:45 a.m. ET .

EU member states can utilize the positive CHMP opinion when making national decisions about use of the antibody cocktail, prior to a potential future EMA market authorization Regeneron has collaborated with Roche to develop and manufacture the antibody cocktail;

The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19

Conference call and webcast to take place on Friday, March 5, 2021 at 8:30 am ET

Strengthened Industry-Centric Leadership Reorganization Initiated to Enhance Operations as Recro Expands Customer Portfolio, Explores Inorganic Growth Opportunities Core Commercial Product Outlook Strong Heading into 2021 Clinical Trials Support Services, Launched in 2020, Continues to Grow Company to Host Conference Call Today at 8:00 a.m. ET

Novel coronavirus findings Exploratory Analysis of Immunization Records Highlights Decreased SARS-CoV-2 Rates in Individuals with Recent Non-COVID-19 Vaccinations published in peer-reviewed Scientific Reports